LIVE TRIAL INDEX试验名称/注册号疾病与阶段状态、地点与更新详情
多疾病活跃状态临床试验
覆盖乳腺癌、结直肠癌、前列腺癌、白血病、淋巴瘤、脑肿瘤、心衰、卒中、多发性硬化和罕见病；去重完整索引 37,542 项，当前页面展示最近更新的 300 项。本站数据同步于 2026-08-15T06:11:14.687Z。
试验状态和地点会变化，本站记录不等于适合、可入组或研究中心已接受咨询，行动前必须打开官方记录复核。
300 项匹配
NCT06875310A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
lung-cancerPHASE3招募中 · 351个地点Mirati Therapeutics Inc. · 更新于 2026-08-14查看试验详情 →NCT07365241A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
lung-cancerPHASE3招募中 · 46个地点AbbVie · 更新于 2026-08-14查看试验详情 →NCT07388524Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
lung-cancerPHASE3招募中 · 36个地点National Cancer Institute (NCI) · 更新于 2026-08-14查看试验详情 →NCT06743555Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study
lung-cancerPHASE1尚未开始招募 · 1个地点Centre hospitalier de l'Université de Montréal (CHUM) · 更新于 2026-08-14查看试验详情 →NCT06568939A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
lung-cancerPHASE2招募中 · 80个地点AbbVie · 更新于 2026-08-14查看试验详情 →NCT06253520Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
lung-cancer / 乳腺癌 / 结直肠癌 / ovarian-cancerPHASE1进行中，停止招募 · 1个地点National Cancer Institute (NCI) · 更新于 2026-08-14查看试验详情 →NCT06312137A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
lung-cancerPHASE3招募中 · 268个地点Merck Sharp & Dohme LLC · 更新于 2026-08-14查看试验详情 →NCT06822543A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
lung-cancer / 脑肿瘤PHASE2招募中 · 13个地点Latin American Cooperative Oncology Group · 更新于 2026-08-14查看试验详情 →NCT07005297Clinical Genetics Branch Eligibility Screening Survey
lung-cancer / melanoma未标明阶段尚未开始招募 · 1个地点National Cancer Institute (NCI) · 更新于 2026-08-14查看试验详情 →NCT05538130A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
lung-cancer / 脑肿瘤 / cervical-cancer / melanomaPHASE1招募中 · 83个地点Pfizer · 更新于 2026-08-14查看试验详情 →NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
lung-cancerPHASE2招募中 · 1个地点Centre hospitalier de l'Université de Montréal (CHUM) · 更新于 2026-08-14查看试验详情 →NCT04267848Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
lung-cancerPHASE3招募中 · 1150个地点National Cancer Institute (NCI) · 更新于 2026-08-14查看试验详情 →NCT06772623Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
lung-cancerPHASE1 / PHASE2招募中 · 118个地点AbbVie · 更新于 2026-08-14查看试验详情 →NCT06627647A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
lung-cancerPHASE3招募中 · 295个地点AstraZeneca · 更新于 2026-08-14查看试验详情 →NCT06646276A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
lung-cancerPHASE3招募中 · 183个地点Bristol-Myers Squibb · 更新于 2026-08-14查看试验详情 →NCT07701733A Study of Lung Cancer Risk
lung-cancer未标明阶段招募中 · 7个地点Memorial Sloan Kettering Cancer Center · 更新于 2026-08-14查看试验详情 →NCT06120803Esomeprazole and Radiation Induced Esophagitis
lung-cancerPHASE2招募中 · 1个地点Rush University Medical Center · 更新于 2026-08-14查看试验详情 →NCT07509034Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
lung-cancerPHASE1尚未开始招募 · 1个地点National Cancer Institute (NCI) · 更新于 2026-08-14查看试验详情 →NCT06995898The Vanguard Study: Testing a New Way to Screen for Cancer
lung-cancer / 乳腺癌 / 结直肠癌 / 前列腺癌 / gastric-cancer / liver-cancer / pancreatic-cancer / ovarian-cancer / cervical-cancerNA招募中 · 40个地点National Cancer Institute (NCI) · 更新于 2026-08-14查看试验详情 →NCT07766538Feasibility and Uptake of Low-Dose CT Lung Cancer Screening in Kuwait
lung-cancerNA尚未开始招募 · 1个地点Sulaiman Khadadah · 更新于 2026-08-14查看试验详情 →NCT05853575Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
lung-cancerPHASE2进行中，停止招募 · 98个地点Mirati Therapeutics Inc. · 更新于 2026-08-14查看试验详情 →NCT07155174A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
lung-cancerPHASE2招募中 · 63个地点AbbVie · 更新于 2026-08-14查看试验详情 →NCT03412877Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
lung-cancer / 乳腺癌 / ovarian-cancerPHASE2招募中 · 1个地点National Cancer Institute (NCI) · 更新于 2026-08-14查看试验详情 →NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
lung-cancer / 淋巴瘤PHASE3进行中，停止招募 · 195个地点Merck Sharp & Dohme LLC · 更新于 2026-08-14查看试验详情 →NCT05466149Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
lung-cancerPHASE2进行中，停止招募 · 1个地点Allist Pharmaceuticals, Inc. · 更新于 2026-08-14查看试验详情 →